Should I buy or sell VolitionRx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks .

What is VolitionRx's stock price target for 2024?

1 brokers have issued 1-year target prices for VolitionRx's shares. Their VNRX share price targets range from $2.50 to $2.50. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 305.1% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts .

How have VNRX shares performed in 2024?

VolitionRx's stock was trading at $0.7170 at the start of the year. Since then, VNRX shares have decreased by 13.9% and is now trading at $0.6172. View the best growth stocks for 2024 here .

When is VolitionRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VNRX earnings forecast .

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSE:VNRX) announced its quarterly earnings results on Monday, March, 25th. The company reported ($0.11) EPS for the quarter. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.50 million.

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free VNRX Stock Alerts

$0.62

+0.02 (+3.35%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.60
▼
$0.65
50-Day Range: $0.60
▼
$1.13
52-Week Range: $0.55
▼
$2.10

Volume: 255,738 shs
Average Volume: 154,929 shs
Market Capitalization: $50.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Get VolitionRx alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About VolitionRx Stock (NYSE:VNRX)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

VNRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VNRX Stock News Headlines

April 18, 2024 | americanbankingnews.com

VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

April 11, 2024 | americanbankingnews.com

Zacks Small Cap Comments on VolitionRx Limited's FY2024 Earnings (NYSE:VNRX)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 11, 2024 | americanbankingnews.com

Critical Review: VolitionRx (NYSE:VNRX) vs. Global WholeHealth Partners (OTCMKTS:GWHP)

April 10, 2024 | americanbankingnews.com

VolitionRx Limited (NYSE:VNRX) to Post Q1 2024 Earnings of ($0.11) Per Share, Zacks Small Cap Forecasts

April 8, 2024 | msn.com

VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...

April 8, 2024 | finance.yahoo.com

VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis

March 25, 2024 | msn.com

VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 25, 2024 | prnewswire.com

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

March 22, 2024 | benzinga.com

Earnings Outlook For VolitionRX

March 21, 2024 | prnewswire.com

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

March 21, 2024 | finanznachrichten.de

VolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical Officer

March 19, 2024 | markets.businessinsider.com

VolitionRx Names Andrew Retter Chief Medical Officer

March 19, 2024 | finance.yahoo.com

Volition appoints Dr Andrew Retter as Chief Medical Officer

March 19, 2024 | money.usnews.com

VolitionRX Ltd

February 22, 2024 | benzinga.com

VolitionRX Stock (AMEX:VNRX), Short Interest Report

January 2, 2024 | msn.com

VolitionRx stock soars after company discloses $13M in milestone payments

January 2, 2024 | realmoney.thestreet.com

VolitionRx milestone payment 'important step forward,' says EF Hutton

November 17, 2023 | finance.yahoo.com

Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society

November 8, 2023 | proactiveinvestors.com

VolitionRx to host Q3 earnings call on November 15

October 28, 2023 | markets.businessinsider.com

VolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s Perspective

See More Headlines

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: N/A
Current Symbol: NYSE:VNRX
CUSIP: N/A
CIK: 93314
Web: N/A
Phone: 646-650-1351
Fax: 65 32 8172 5651
Employees: 110
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $2.50
Low Stock Price Target: $2.50
Potential Upside/Downside: +305.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,320,000.00
Net Margins: -4,557.29%
Pretax Margin: -4,603.48%
Return on Equity: N/A
Return on Assets: -154.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.69
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $770,000.00
Price / Sales: 65.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.11) per share
Price / Book: -5.61

Miscellaneous

Outstanding Shares: 82,070,000
Free Float: 69,430,000
Market Cap: $50.65 million
Optionable: Optionable
Beta: 1.35

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Martin Charles Faulkes Ph.D. (Age 80)
Executive Chairman
Comp: $227.63k
Mr. Cameron Reynolds MBA (Age 53)
Founder, CEO, President & Director
Comp: $538.66k
Dr. Jacob Vincent Micallef MBA (Age 68)
Ph.D., Chief Scientific Officer
Comp: $571.55k
Mr. Nicholas Plummer (Age 53)
Group General Counsel
Mr. Gael Forterre M.B.A. (Age 42)
Chief Commercial Officer
Ms. Sharon Ballesteros
U.S. Head of Quality & Development Process
Mr. Rodney Gerard Rootsaert LLB (Age 53)
Corporate Secretary
Comp: $126.23k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNRX Stock Analysis - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings or view top-rated stocks.
What is VolitionRx's stock price target for 2024?: 1 brokers have issued 1-year target prices for VolitionRx's shares. Their VNRX share price targets range from $2.50 to $2.50. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 305.1% from the stock's current price.
View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts.
How have VNRX shares performed in 2024?: VolitionRx's stock was trading at $0.7170 at the start of the year. Since then, VNRX shares have decreased by 13.9% and is now trading at $0.6172.
View the best growth stocks for 2024 here.
When is VolitionRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VNRX earnings forecast.

How were VolitionRx's earnings last quarter?: VolitionRx Limited (NYSE:VNRX) announced its quarterly earnings results on Monday, March, 25th. The company reported ($0.11) EPS for the quarter. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.50 million.
How do I buy shares of VolitionRx?: Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:VNRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial